학술논문

Integrating artificial intelligence into lung cancer screening: a randomised controlled trial protocol
Document Type
article
Author
Paul HofmanSylvie LeroyJonathan BenzaquenBernard PadovaniCharles Hugo MarquetteFontas EricEric FontasStephanie LopezNesrine RouisJacques BoutrosAllegra MarylineAmamou-Elhani FatenARFI ThierryBaque JeanBaque-Juston MarieBarel RemyBarrios Baretto DeisyBaudin GuillaumeBeck CamilleBellmann LaurentBenchetrit MaximeBenkirane Mohamed-TaibBenyoussef Sid AliBenzaquen JonathanBerthet Jean PhilippeBonnard EricBordone OlivierBoutros JacquesBoyer Guy-RenéBulsei JulieCaillon CynthiaCastelnau OlivierChalmin JérémyChebib RalphCohen CharlotteCruzel CoralieDegoutte AurélienDelin MargotDiascorn YannDoux NathalieDurand LorraineDuval YannickEl Hemweh OmarFayada JulienFelderhoof EricFeliciello Stéphane:Femenia RichardFerrari VictoriaFrancisci Marc PaulGhalloussi HannahGomez-Caro-Andres AbelGora AssiaGriffonnet JenniferGubeno Marie ChristineGuigay JoëlHamila MarameHarrathi Mohamed-AliHenaut QuentinHerin EdouardHofman PaulHofman VéroniqueILIE MariusKorzeniewski SylviaLalvee SaloméLassalle SandraLe Heron CharlesLeray LoïcLeriche JulienLerousseau LionelLeroy SylvieLespinet Fabre VirginieLestrez RoxaneLeyssalle AxelleLong Mira ElodieLopez StephanieMahler ValentinManiel CharlotteMarcano XavierMarco Roucayrol SabineMarquette Charles-HugoMartin NicolasMistri AurélieNicolle IsabelleNovellas SébastienOddo FrédéricOtto JosianePadovani BernardPERQUIS Marie PierrePhilibert LorènePop DanielPottier HéloïseRaguin OlivierRolland FabienRouis NesrineRousset JohannaRuitort FrédéricSanfiorenzo CélineSelva EricTanga VirginieTardy MagalieThomas OlivierVarenio SophieVerdoire PaulVigny IsabelleWashetine KévinZurlinden OlivierTarhini AdamPerrotin Cédric
Source
BMJ Open, Vol 14, Iss 2 (2024)
Subject
Medicine
Language
English
ISSN
2044-6055
Abstract
Introduction Lung cancer (LC) is the most common cause of cancer-related deaths worldwide. Its early detection can be achieved with a CT scan. Two large randomised trials proved the efficacy of low-dose CT (LDCT)-based lung cancer screening (LCS) in high-risk populations. The decrease in specific mortality is 20%–25%.Nonetheless, implementing LCS on a large scale faces obstacles due to the low number of thoracic radiologists and CT scans available for the eligible population and the high frequency of false-positive screening results and the long period of indeterminacy of nodules that can reach up to 24 months, which is a source of prolonged anxiety and multiple costly examinations with possible side effects.Deep learning, an artificial intelligence solution has shown promising results in retrospective trials detecting lung nodules and characterising them. However, until now no prospective studies have demonstrated their importance in a real-life setting.Methods and analysis This open-label randomised controlled study focuses on LCS for patients aged 50–80 years, who smoked more than 20 pack-years, whether active or quit smoking less than 15 years ago. Its objective is to determine whether assisting a multidisciplinary team (MDT) with a 3D convolutional network-based analysis of screening chest CT scans accelerates the definitive classification of nodules into malignant or benign. 2722 patients will be included with the aim to demonstrate a 3-month reduction in the delay between lung nodule detection and its definitive classification into benign or malignant.Ethics and dissemination The sponsor of this study is the University Hospital of Nice. The study was approved for France by the ethical committee CPP (Comités de Protection des Personnes) Sud-Ouest et outre-mer III (No. 2022-A01543-40) and the Agence Nationale du Medicament et des produits de Santé (Ministry of Health) in December 2023. The findings of the trial will be disseminated through peer-reviewed journals and national and international conference presentations.Trial registration number NCT05704920.